{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:09:39Z","timestamp":1784038179912,"version":"3.55.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is a heterogeneous disease with complex mutational profiles that lead to variable clinical outcomes. NRAS and KRAS are among the most frequently mutated genes in AML, but their clinical impact has not been well characterized. In this cohort of &amp;gt;2000 children and young adults with AML, we evaluated the role of mutations in RAS genes and mutation complexity in outcome determination. Given enrichment in KMT2A-rearranged (KMT2A-r) AML, we specifically studied the significance of RAS mutations in KMT2A-r AML. Using variant calls from next-generation sequencing platforms, we identified RAS mutations in 35.1% (N = 669; NRAS, n = 518; KRAS, n = 216). We demonstrated that NRAS mutations were not associated with outcome in AML or in KMT2A-r AML. In contrast, KRAS mutations demonstrated inferior outcomes in AML, with enrichment of prevalence and enhancement of prognostic implications in KMT2A-r AML, including non\u2013high-risk KMT2A fusions. Additionally, we describe a complex RAS (Comp-RAS) mutation cohort characterized by 2 distinct RAS mutations or high variant allele frequency RAS mutations that collectively account for 13.5% (n = 90) of the patients with RAS mutations. Patients with complex KRAS mutations and those with Comp-RAS mutations in the KMT2A-r cohort had a distinctly adverse outcome, and data demonstrate that Comp-RAS status drives adverse outcomes for those with KRAS mutations in the whole AML cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018699","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:06:28Z","timestamp":1778609188000},"page":"4814-4827","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8590-8426","authenticated-orcid":false,"given":"John N.","family":"Colgan","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Pediatrics, University of Washington, Seattle, WA"},{"name":"3School of Clinical Medicine, University of New South Wales, Children\u2019s Cancer Institute, Kensington, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5097-0652","authenticated-orcid":false,"given":"Jack H.","family":"Peplinski","sequence":"additional","affiliation":[{"name":"4Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"5Children\u2019s Oncology Group, Arcadia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-9416","authenticated-orcid":false,"given":"Danielle C.","family":"Kirkey","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, University of Washington, Seattle, WA"},{"name":"4Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan K.","family":"Wallace","sequence":"additional","affiliation":[{"name":"4Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8932-4405","authenticated-orcid":false,"given":"Yuan","family":"Feng","sequence":"additional","affiliation":[{"name":"6Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[{"name":"6Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-9282","authenticated-orcid":false,"given":"Patrick","family":"Connerty","sequence":"additional","affiliation":[{"name":"3School of Clinical Medicine, University of New South Wales, Children\u2019s Cancer Institute, Kensington, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3702-7923","authenticated-orcid":false,"given":"Rhonda E.","family":"Ries","sequence":"additional","affiliation":[{"name":"4Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7781-2918","authenticated-orcid":false,"given":"Adam","family":"Lamble","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-0833","authenticated-orcid":false,"given":"Benjamin J.","family":"Huang","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, University of California, Benioff Children\u2019s Hospital, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"5Children\u2019s Oncology Group, Arcadia, CA"},{"name":"8Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-2145","authenticated-orcid":false,"given":"Xiaotu","family":"Ma","sequence":"additional","affiliation":[{"name":"6Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tarlock","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, University of Washington, Seattle, WA"},{"name":"4Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"1","key":"2026071409564878500_bib1","first-page":"75","article-title":"Pediatric acute myeloid leukemia: biology and therapeutic implications of genomic variants","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr Clin"},{"issue":"1","key":"2026071409564878500_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"2026071409564878500_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat Genet"},{"issue":"6","key":"2026071409564878500_bib4","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood-2005-03-0867","article-title":"RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years","volume":"106","author":"Bowen","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2026071409564878500_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3324\/haematol.2020.269431","article-title":"Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia","volume":"107","author":"Kaburagi","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2026071409564878500_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","article-title":"RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026071409564878500_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2019-125319","article-title":"RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy","volume":"134","author":"Ball","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2026071409564878500_bib8","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-024-02244-4","article-title":"KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia","volume":"38","author":"Iyoda","year":"2024","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026071409564878500_bib9","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2024-205218","article-title":"Codon-specific ifferences in RAS mutations in AML and differential response to therapeutic agents","volume":"144","author":"Anandappa","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026071409564878500_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/leu.2011.31","article-title":"Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group","volume":"25","author":"Berman","year":"2011","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026071409564878500_bib11","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1182\/blood-2022-170747","article-title":"RAS pathway alterations in pediatric AML patients","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026071409564878500_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"2026071409564878500_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.20517\/cdr.2022.130","article-title":"How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?","volume":"6","author":"Perrone","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"9","key":"2026071409564878500_bib14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026071409564878500_bib15","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"issue":"357","key":"2026071409564878500_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005301","article-title":"RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci Signal"},{"issue":"15","key":"2026071409564878500_bib17","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2026071409564878500_bib18","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"2026071409564878500_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"2026071409564878500_bib20","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"2026071409564878500_bib21","article-title":"Revised risk stratification criteria for children with newly diagnosed acute myeloid leukemia: a report from the Children's Oncology Group","volume":"130","author":"Cooper","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2026071409564878500_bib22","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/bloodadvances.2023011771","article-title":"Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia","volume":"8","author":"van Weelderen","year":"2024","journal-title":"Blood Adv"},{"issue":"16","key":"2026071409564878500_bib23","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.22.02120","article-title":"Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-M\u00fcnster Study Group","volume":"41","author":"van Weelderen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026071409564878500_bib24","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1182\/bloodadvances.2020002457","article-title":"Fusion partner\u2013specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML","volume":"4","author":"Matsuo","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2026071409564878500_bib25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"2026071409564878500_bib26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","article-title":"Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group","volume":"111","author":"Lange","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2026071409564878500_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cncr.26190","article-title":"AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group","volume":"118","author":"Cooper","year":"2012","journal-title":"Cancer"},{"issue":"27","key":"2026071409564878500_bib28","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026071409564878500_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib combination therapy in multiple myeloma","volume":"49","author":"Kapoor","year":"2012","journal-title":"Seminars in hematology"},{"issue":"1","key":"2026071409564878500_bib30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-025-01293-x","article-title":"Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group","volume":"15","author":"Zhang","year":"2025","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026071409564878500_bib31","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","article-title":"Rearrangements involving 11q23. 3\/KMT2A in adult AML: mutational landscape and prognostic implications\u2013a HARMONY study","volume":"38","author":"Hern\u00e1ndez-S\u00e1nchez","year":"2024","journal-title":"Leukemia"},{"key":"2026071409564878500_bib32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fonc.2019.00965","article-title":"RAS: striking at the core of the oncogenic circuitry","volume":"9","author":"Gimple","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"2026071409564878500_bib33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ng.115","article-title":"Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon","volume":"40","author":"Haigis","year":"2008","journal-title":"Nat Genet"},{"issue":"5","key":"2026071409564878500_bib34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cell.2017.01.020","article-title":"KRAS allelic imbalance enhances fitness and modulates MAP kinase dependence in cancer","volume":"168","author":"Burgess","year":"2017","journal-title":"Cell"},{"issue":"6","key":"2026071409564878500_bib35","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood-2010-04-280750","article-title":"Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2026071409564878500_bib36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2010-12-326058","article-title":"Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose-and cell type-dependent manner","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026071409564878500_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41467-023-44342-4","article-title":"KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo","volume":"15","author":"Najumudeen","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"2026071409564878500_bib38","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ccell.2018.10.003","article-title":"Widespread selection for oncogenic mutant allele imbalance in cancer","volume":"34","author":"Bielski","year":"2018","journal-title":"Cancer cell"},{"issue":"21","key":"2026071409564878500_bib39","doi-asserted-by":"crossref","first-page":"e159579","DOI":"10.1172\/JCI159579","article-title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade\u2013unresponsive microenvironments in acute myeloid leukemia","volume":"132","author":"Rutella","year":"2022","journal-title":"J Clin Invest"},{"issue":"21","key":"2026071409564878500_bib40","doi-asserted-by":"crossref","first-page":"e120974","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI insight"},{"issue":"12","key":"2026071409564878500_bib41","doi-asserted-by":"crossref","first-page":"e33452","DOI":"10.1016\/j.heliyon.2024.e33452","article-title":"Advances in the role of ion channels in leukemia","volume":"10","author":"Zhu","year":"2024","journal-title":"Heliyon"},{"issue":"4","key":"2026071409564878500_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41419-020-2454-8","article-title":"Transient receptor potential ion channel TRPM2 promotes AML proliferation and survival through modulation of mitochondrial function, ROS, and autophagy","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026071409564878500_bib43","doi-asserted-by":"crossref","first-page":"117161","DOI":"10.1016\/j.lfs.2019.117161","article-title":"LncRNA KCNQ1OT1 contributes to the progression and chemoresistance in acute myeloid leukemia by modulating Tspan3 through suppressing miR-193a-3p","volume":"241","author":"Sun","year":"2020","journal-title":"Life Sci"},{"issue":"6","key":"2026071409564878500_bib44","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/2159-8290.CD-18-1220","article-title":"Tissue-specific oncogenic activity of KRASA146T","volume":"9","author":"Poulin","year":"2019","journal-title":"Cancer Discov"},{"issue":"6","key":"2026071409564878500_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41422-025-01085-9","article-title":"Oncogenic RAS induces a distinctive form of non-canonical autophagy mediated by the P38-ULK1-PI4KB axis","volume":"35","author":"Wang","year":"2025","journal-title":"Cell Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4814\/2531590\/blooda_adv-2025-018699-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4814\/2531590\/blooda_adv-2025-018699-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:56:58Z","timestamp":1784037418000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4814\/568355\/Clinical-implications-of-RAS-mutations-in-AML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":45,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018699","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,7,2]]}}}